Washington State University

Vivos Inc. Initiates First-in-Human Trial of RadioGel® for Cancer Therapy

5 months ago

• Vivos Inc. has begun its first human clinical trial in India for RadioGel® Precision Radionuclide Therapy™ targeting cancerous lymph nodes. • The initial phase of the trial successfully treated five patients, demonstrating precise placement of RadioGel® and focusing on safety. • The study, aligning with a planned Mayo Clinic study, has regulatory approval to expand to 30 patients with various cancerous nodes. • Vivos plans to share trial results with the FDA to support Investigational Device Exemption and expand RadioGel® indications in the U.S.

MediWound Initiates Phase III Trial of EscharEx for Venous Leg Ulcers

5 months ago

• MediWound has commenced a Phase III clinical trial (VALUE) to evaluate EscharEx for the treatment of venous leg ulcers (VLUs). • The VALUE trial is a randomized, double-blind, placebo-controlled study across 40 sites in the U.S. and Europe, enrolling 216 patients. • EscharEx has shown promise in Phase II trials, demonstrating effective and rapid debridement of chronic wounds, potentially redefining VLU treatment. • An interim analysis of the VALUE trial is expected in mid-2026, with strategic collaborations in place to ensure consistent wound management.

CBG Shows Promise in Reducing Anxiety and Enhancing Verbal Memory

7 months ago

• A double-blind, placebo-controlled study found that cannabigerol (CBG) significantly reduced overall feelings of anxiety in cannabis users. • Participants reported no intoxication or significant side effects, and CBG did not impair cognitive or motor functions. • Surprisingly, CBG enhanced verbal memory at 45- and 60-minute check-ins, a finding that warrants further investigation. • The study provides initial scientific evidence supporting the anecdotal use of CBG for anxiety relief, distinguishing it from THC's effects.

Obeticholic Acid Shows Long-Term Benefit in Primary Biliary Cholangitis

9 months ago

• COBALT trial data, published in *The American Journal of Gastroenterology*, shows obeticholic acid (OCA) significantly reduces adverse outcomes in PBC patients. • The study compared OCA-treated patients to an external control arm derived from real-world U.S. claims data. • OCA treatment was associated with a 61% lower relative risk of death, liver transplant, or hepatic decompensation (HR, 0.39; P=0.0010). • Findings support the use of external control arms in rare disease trials, where placebo groups pose ethical and practical challenges.

Dog Aging Project Seeks Canine Volunteers for Longevity Research

10 months ago

• The Dog Aging Project (DAP) is a five-year study aiming to understand aging in dogs, potentially benefiting human health as well. • Researchers seek diverse canine participants, including large breeds, working dogs, and puppies, to study genetic and environmental factors. • A clinical trial within the DAP investigates rapamycin's effect on canine lifespan and healthspan, building on promising results in mice. • Dog owners can nominate their dogs at DogAgingProject.org, contributing to a large-scale community science effort with global research impact.

One-Week Elderberry Juice Treatment Increases Postprandial Carbohydrate Oxidation

2 years ago

A pilot study found that consuming 100% elderberry juice for one week significantly increased postprandial carbohydrate oxidation in overweight and obese adults, without affecting serum glucose or insulin levels. The study suggests elderberry juice could influence metabolic flexibility, though further research is needed to confirm these findings.